about
Advanced new strategies for metastatic cancer treatment by therapeutic stem cells and oncolytic virotherapy.Inhibition of 6-phosphofructo-2-kinase (PFKFB3) suppresses glucose metabolism and the growth of HER2+ breast cancer.The HER2 CISH pharmDx(™) Kit in the assessment of breast cancer patients for anti-HER2 treatment.Everolimus in Breast Cancer: The Role of the Pharmacist.Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Utility of a Novel Three-Dimensional and Dynamic (3DD) Cell Culture System for PK/PD Studies: Evaluation of a Triple Combination Therapy at Overcoming Anti-HER2 Treatment Resistance in Breast Cancer.
P2860
Q37629088-4E3CB453-6AC7-4E40-97B2-DC243FE50C81Q39405012-F28A9938-383C-4D6E-9869-9E8D84CD2F88Q46431111-2ECC6731-B84B-42D8-991E-68AE3A777CB5Q46458593-33AFBB9F-32C1-44FC-A034-AE1F8D914600Q46727800-C960255F-8522-4E36-9EA0-33CBDA82188EQ49511046-F01F97F1-58A8-42B3-B6DC-B06267220DDFQ54979012-CCBF4C98-C5CE-460D-A599-4862323C404C
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Target points in trastuzumab resistance
@ast
Target points in trastuzumab resistance
@en
type
label
Target points in trastuzumab resistance
@ast
Target points in trastuzumab resistance
@en
prefLabel
Target points in trastuzumab resistance
@ast
Target points in trastuzumab resistance
@en
P2093
P2860
P356
P1476
Target points in trastuzumab resistance
@en
P2093
Abbas Rahimi Shamabadi
Mossa Gardaneh
Sahar Shojaei
P2860
P304
P356
10.1155/2012/761917
P577
2012-02-26T00:00:00Z